Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued on Tuesday. The firm set a “sell” rating on the stock.

Separately, Dawson James assumed coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday, February 28th. They set a “buy” rating and a $3.00 price target on the stock.

Tonix Pharmaceuticals Trading Up 3.3 %

NASDAQ TNXP opened at $0.19 on Tuesday. The company has a market capitalization of $18.15 million, a PE ratio of -0.03 and a beta of 2.16. Tonix Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $2.10. The company has a current ratio of 1.47, a quick ratio of 0.87 and a debt-to-equity ratio of 0.06. The firm’s fifty day simple moving average is $0.21 and its 200-day simple moving average is $0.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Monday, April 1st. The company reported ($0.86) earnings per share for the quarter. The firm had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.95 million. As a group, sell-side analysts anticipate that Tonix Pharmaceuticals will post -3.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC bought a new stake in Tonix Pharmaceuticals during the third quarter worth approximately $790,000. Sabby Management LLC bought a new position in shares of Tonix Pharmaceuticals in the third quarter valued at approximately $680,000. Finally, Acadian Asset Management LLC lifted its stake in shares of Tonix Pharmaceuticals by 260.6% in the first quarter. Acadian Asset Management LLC now owns 335,373 shares of the company’s stock worth $61,000 after buying an additional 242,358 shares during the last quarter. Institutional investors and hedge funds own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.